Clinical Trial Update: A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating DFV890 for reducing inflammatory markers in adults with coronary heart disease and elevated hsCRP has completed with results posted (Ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Heart Disease

Drugs mentioned

• DFV890

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Coronary Heart Disease | Phase 2 | Status: COMPLETED | Results posted: 2026-03-27